Table 4.

Concomitant use with other CIU/CSU medications at index date and treatment changes associated with omalizumab (N = 1546)

CIU = chronic idiopathic urticaria; CSU = chronic spontaneous urticaria; SD = standard deviation; Q1 = quartile 1; Q3 = quartile 3; IQR = interquartile range.

*Concomitant use was defined as a continuous use of a CIU/CSU medication (no gap of ≥30 days between consecutive days of supply) for ≥30 days after omalizumab initiation.

#Anti-inflammatory agents included hydroxychloroquine, dapsone, colchicine, and sulfasalazine.

§Immunosuppressive agents included cyclosporine, mycophenolate, and methotrexate.

¶Discontinuation was defined as a gap of ≥90 days between consecutive days of omalizumab supply or between the last day of omalizumab supply and the end of the follow-up period.

‖Switch was defined as a prescription fill for another CIU/CSU medication during the 90-day period after omalizumab discontinuation; the new treatment had to be either discontinued or never used before the switch date.

**Restart was defined as a gap of ≥90 days between consecutive days of omalizumab supply.

##Add-on was defined as an overlap in continuous use of omalizumab and another CIU/CSU treatment not used concomitantly at the index date, with one or more refills of omalizumab during the overlap.